Jul 13, 2021 / 03:00PM GMT
Matthew Kaplan - Ladenburg Thalmann & Co. Inc. - Analyst
I'd like to introduce our next presenting company, Lipocine. Presenting for the Company is Dr. Mahesh Patel, CEO. Mahesh, please walk us through the story. And hopefully we'll have some time for some Q&A afterwards. And thanks for joining us today and the floor is yours, Mahesh.
Mahesh Patel - Lipocine Inc. - Chairman, President & CEO
Thanks, Matt. It's my pleasure. Good day to everyone. I am Mahesh Patel; I am the President, CEO and Cofounder of Lipocine. I'm delighted to update you on our innovative and advancing pipeline, but let's get the forward-looking statement out of the way. I'll give you a few moments to -- all right, let's dive into our robust pipeline.
We are focused on developing innovative products for metabolic and endocrine disorders. We have one product that's standard. It would be approved. Two that are essentially Phase 3 really, and three in Phase 2 development. Our candidates are in three buckets -- testosterone replacement therapy, TLANDO. It is our convenient
Lipocine Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot